We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Pruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
Jay Reddy, MD, FASN
Carlos Narváez Mejía, MD
Understanding the Recent Advances in IgAN
Jürgen Floege, MD
Jonathan Barratt, PhD
I Just Need to Sleep! Improving Itch in Patients With CKD-aP
Kieran McCafferty, MD
Prof. Dr. Jörg Latus
Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
Terry Faleye, MPAS, PA-C
Jonathan I. Silverberg, MD, PhD, MPH
Why We Should Be PRO Patients With CKD-Associated Pruritus
Lucio Manenti, MD, PhD
Jeanette Finderup, PhD, MHR, RN
Sebastian Koball, MD
Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation
Cara Dolin, MD
Jennifer Simpson
Diana Girnita, MD ,PhD
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Jeffrey S. Weber, MD, PhD
Sapna Patel, MD
Jason J. Luke, MD, FACP
Holding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
Omid Hamid, MD
Ryan Sullivan, MD
Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education